Table 1. Baseline characteristics of 28 patients who received leflunomide .

Mean age (y) ± SD	51.9 ± 13.1
Male, n (%)	25 (89)
Transplant type, n (%)
Kidney	26 (93)
Kidney –Pancreas	2 (7)
Induction immunosuppression therapy , n (%
Antithymocyte globulin (rabbit))	16 (57)
Alemtuzumab	8 (29)
Basiliximab	1 (3)
Unknown induction	3 (11)
Maintenance immunosuppression therapy, n (%
Tacrolimus, MMF, prednisone	20 (71)
Tacrolimus, MMF	5 (18)
Tacrolimus, prednisone	2 (7)
Tacrolimus alone	1 (4)
Creatinine at diagnosis, (mg/dL); mean (IQR), n (%)	2 (1.5-2.4)
Tacrolimus level at diagnosis, (ng/mL); mean (IQR), n (%)	8.7 (5.5-10.4)

Abbreviation: IQR, interquartile range.